Naprosyn

Legal status and availability in the UK

In the UK, most naproxen strengths and formulations are prescription-only medicines.

In our online pharmacy, Naprosyn is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Basic Naprosyn information

• INN (international nonproprietary name): Naproxen
• Brand names available in the United Kingdom: Naprosyn; EC-Naprosyn
• ATC code: M01AE02
• Forms & dosages: Oral tablets 250mg and 500mg; delayed‑release (gastro-resistant) tablets 375mg and 500mg; oral suspension.
• Manufacturers: Roche (originator); Teva; Sandoz; Torrent
• Registration status in the United Kingdom: Prescription-only medicine for most strengths and formulations
• OTC / Rx classification: Prescription only (Rx) for most strengths and formulations.

Clinical effectiveness in the UK

Do NHS patients get meaningful pain relief from naproxen and what stops them staying on it?

Within NHS practice, naproxen is routinely prescribed for inflammatory joint disease and episodic moderate pain when paracetamol or topical agents are insufficient.

Naproxen provides meaningful pain reduction and improved function for many chronic osteoarthritis and rheumatoid arthritis patients, especially when combined with physiotherapy.

Discontinuation commonly stems from gastrointestinal upset, hypertension or renal function deterioration, which is why NHS guidance stresses the lowest effective dose for the shortest time and regular monitoring of blood pressure, renal function and haemoglobin.

Hospital rheumatology clinics continue to use naproxen as a first‑line oral NSAID where COX‑2 inhibitors or topical options are unsuitable.

• Expected benefits: reduced pain, improved mobility, fewer days needing rescue analgesia.
• Common reasons for stopping: Stomach upset, raised blood pressure, worsening renal tests.

Indications and expanded uses

What is naproxen licensed for, and where do clinicians commonly use it beyond the licence?

MHRA lists naproxen for inflammatory musculo‑skeletal conditions, acute gout, dysmenorrhoea and short‑term moderate pain control, and NHS formularies reflect these indications.

Standard adult dosages used in clinical practice include arthritis dosing of 250–500mg twice daily and acute gout regimens starting with 750mg then 250mg every 8 hours.

Off‑label but commonly practised uses in NHS and private clinics include tendonitis, bursitis, perioperative soft‑tissue pain and some chronic pain plans where alternatives have failed.

In paediatrics, naproxen suspension and weight‑based dosing (approximately 10mg/kg/day in divided doses) are used for juvenile idiopathic arthritis, and naproxen is not typically recommended under two years.

1. MHRA‑approved uses: Rheumatoid and osteoarthritis, ankylosing spondylitis, acute gout, dysmenorrhoea, short‑term moderate pain relief.
2. Common off‑label uses: Tendonitis, bursitis, perioperative soft‑tissue pain, chronic pain where alternatives unsuitable.

Composition and brand landscape

What formulations and brands are stocked by prescribers and pharmacies in the UK?

The active ingredient is naproxen, available as naproxen sodium or naproxen free acid, classified under ATC M01AE02.

In the UK the range includes branded Naprosyn and generics from manufacturers such as Teva and Sandoz.

Available forms include oral tablets in 250–500mg ranges, delayed‑release (gastro-resistant) formulations and liquid suspensions for children; packaging is usually blister packs of 10, 20, 30 or 50 tablets or suspension bottles for paediatrics.

Note that most standard strengths of naproxen are prescription-only in the UK.

Contraindications and special precautions

Who must not take naproxen and who needs close monitoring?

• Absolute contraindications: Known hypersensitivity to naproxen or other NSAIDs, active peptic ulceration or GI bleeding, recent coronary artery bypass graft surgery, severe heart failure.
• Relative contraindications: Established cardiovascular disease or uncontrolled hypertension, chronic kidney disease, significant hepatic impairment, NSAID‑sensitive asthma, advanced age.

Pregnancy: avoid in the third trimester; use caution while breastfeeding.

Practical UK patient advice includes avoiding concurrent anticoagulants unless supervised, limiting alcohol to reduce GI bleed risk and exercising caution with driving if drowsy or dizzy.

Red flags — do not prescribe if there is active GI bleeding, recent CABG, history of severe NSAID allergy or decompensated heart failure.

Dosage guidelines

How should naproxen be dosed across age groups and conditions?

NHS standard regimens align with established practice: osteoarthritis and rheumatoid arthritis typically 250–500mg twice daily.

Dysmenorrhoea dosing commonly starts at 500mg then 250mg every 6–8 hours as needed, within daily maximum limits.

For acute gout follow the 750mg initial dose then 250mg every 8 hours until the flare settles.

Paediatric dosing is weight‑based at approximately 10mg/kg/day in divided doses, using suspension formulations, and naproxen is not usually recommended under two years.

Missed dose advice: take as soon as remembered unless it is almost time for the next dose; do not double up.

Interactions overview

Which medicines and substances commonly interact with naproxen?

Naproxen increases bleeding risk when combined with anticoagulants or antiplatelet drugs and with SSRIs, and it can blunt the effect of ACE inhibitors, angiotensin receptor blockers and diuretics.

It can raise lithium and methotrexate levels and adds renal risk when used with other nephrotoxic drugs or diuretics.

Alcohol potentiates gastrointestinal toxicity and herbal supplements should be treated with caution.

Comparable medicines and preferences

Which alternatives should prescribers consider when choosing an NSAID?

Naproxen competes with ibuprofen, diclofenac, celecoxib and meloxicam and key differentiators include naproxen’s longer half‑life and less frequent dosing compared with ibuprofen and a comparable gastrointestinal risk to other non‑selective NSAIDs.

Ibuprofen is often favoured for short‑term OTC use because of rapid onset, diclofenac may help localised pain but carries higher cardiovascular warnings, and celecoxib can be an option for patients at higher GI risk though with cardiovascular considerations.

Before choosing naproxen or an alternative, consider pain type, comorbidity (GI vs CV risk), renal function and patient preference.

Frequently asked questions

Q: Is naproxen safe for period pain?

A: Yes for most women; typical regimen starts with 500mg then 250mg PRN within recommended daily limits and after GP advice if there are other health concerns.

Q: Can I take naproxen with my blood pressure tablets?

A: NSAIDs can reduce the effect of antihypertensive drugs; check with your GP or pharmacist and have blood pressure monitored.

Q: What should I do if I develop stomach pain or black stools?

A: Stop naproxen and seek urgent GP or emergency department review as these may indicate gastrointestinal bleeding.

Q: Do I need a prescription for naproxen in the UK?

A: Yes, for most standard strengths – naproxen is a prescription-only medicine in the UK.

Red flags: if you experience severe abdominal pain, vomiting blood or black tarry stools, seek urgent medical attention.

Guidelines for proper use

How should pharmacists counsel patients to use naproxen safely?

When dispensing, assess the indication, check allergy history and anticoagulant use, review blood pressure and renal history, advise taking with food and avoiding excess alcohol, and record advice in the patient record or NHS app.

Counsel on correct dose and timing, explain signs of GI bleed and when to stop, and for long‑term users schedule baseline and periodic BP, renal and haemoglobin checks.

Provide written leaflets and signpost NHS.uk pages and the MHRA Yellow Card scheme for adverse‑event reporting, and advise storage at 15–30°C in the original packaging, out of reach of children.

1. Assess indication, allergies and concurrent medicines.
2. Advise to take with food and avoid alcohol and other NSAIDs.
3. Set monitoring plan for long‑term users (BP, creatinine, haemoglobin).
4. Document counselling in patient record or NHS portal and provide written information.

Delivery across the United Kingdom